Metagenomi Inc (MGX)

$1.75 -0.04 (-2.23%)
Market Cap 67.18M
Revenue (ttm) 52.30M
Net Income (ttm) -78.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -149.25%
Debt to Equity Ratio 0.00
Volume 284,600
Avg Vol 382,608
Day's Range N/A - N/A
Shares Out 37.53M
Stochastic %K 61%
Beta 0.50
Analysts Strong Sell
Price Target $9.33

Company Profile

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensi...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 871 4880
Address:
5959 Horton Street, 7th Floor, EmeryVille, United States
Acs375
Acs375 Jul. 6 at 3:58 PM
$MGX i heard that a bankruptcy is incoming. how true is that?
1 · Reply
Nanu108
Nanu108 Jun. 24 at 10:57 PM
$MGX I have a large position.
0 · Reply
focafoca99
focafoca99 Jun. 5 at 7:52 PM
$MGX faces a law-firm investigation over alleged fiduciary breaches by insiders.
1 · Reply
KHG1962
KHG1962 May. 28 at 10:06 PM
$MGX four posts in one month.
0 · Reply
KHG1962
KHG1962 May. 27 at 1:29 AM
$MGX No clue why I actually own this......
0 · Reply
Sam1381
Sam1381 May. 19 at 2:10 PM
$MGX 1.24$ so far today! Historic low 1.23$ New ATLs coming I gyess!
1 · Reply
anachartanalyst
anachartanalyst May. 12 at 2:02 PM
$MGX https://anachart.com/wp-content/uploads/2026/05/1778594491_soc-img.jpg
0 · Reply
BillionerOfKing
BillionerOfKing May. 1 at 4:19 PM
$MGX Current Stock Price: $1.38
0 · Reply
MikeEhrmantraut
MikeEhrmantraut Apr. 22 at 2:27 PM
$MGX trash and pure management grift. Should be a university research department not a publicly traded company.
0 · Reply
Mindegap
Mindegap Apr. 20 at 7:50 PM
If I were short I would be nervous right now. Covering would be a very good option. $ABSI, $PRME, $MGX, $CRBU, $MXCT
1 · Reply
Latest News on MGX
Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio

Jul 15, 2026, 8:00 AM EDT - 1 hour ago

Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio

CLLS

Metagenomi transferred with a Buy at Chardan

2026-07-07T10:40:09.000Z - 8 days ago

Metagenomi transferred with a Buy at Chardan

Metagenomi Therapeutics Transcript: AGM 2026

Jun 9, 2026, 11:00 AM EDT - 5 weeks ago

Metagenomi Therapeutics Transcript: AGM 2026

Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Jun 5, 2026, 3:45 PM EDT - 5 weeks ago

Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Metagenomi Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 7:35 AM EDT - 5 weeks ago

Metagenomi Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference

May 28, 2026, 8:00 AM EDT - 6 weeks ago

Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference

Metagenomi price target lowered to $9 from $12 at Wells Fargo

2026-05-12T10:27:58.000Z - 2 months ago

Metagenomi price target lowered to $9 from $12 at Wells Fargo

Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

May 11, 2026, 4:05 PM EDT - 2 months ago

Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

Metagenomi Therapeutics Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 2 months ago

Metagenomi Therapeutics Earnings release: Q1 2026

Metagenomi Therapeutics Quarterly report: Q1 2026

May 11, 2026, 4:00 PM EDT - 2 months ago

Metagenomi Therapeutics Quarterly report: Q1 2026

Metagenomi Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Metagenomi Therapeutics Proxy statement: Proxy filing

Metagenomi Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Metagenomi Therapeutics Proxy statement: Proxy filing

Metagenomi announces publication on MG119-28

2026-04-16T12:07:08.000Z - 3 months ago

Metagenomi announces publication on MG119-28

Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency

Apr 16, 2026, 7:00 AM EDT - 3 months ago

Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency

Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results

Mar 5, 2026, 4:05 PM EST - 4 months ago

Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results

Metagenomi Therapeutics Annual report: Q4 2025

Mar 5, 2026, 3:00 PM EST - 4 months ago

Metagenomi Therapeutics Annual report: Q4 2025

Metagenomi Therapeutics Earnings release: Q4 2025

Mar 5, 2026, 3:00 PM EST - 4 months ago

Metagenomi Therapeutics Earnings release: Q4 2025

Metagenomi Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 11:10 AM EST - 4 months ago

Metagenomi Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference

Feb 23, 2026, 4:05 PM EST - 5 months ago

Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference

Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook

Jan 12, 2026, 8:30 AM EST - 6 months ago

Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook

Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference

Dec 1, 2025, 7:00 AM EST - 8 months ago

Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference

Metagenomi Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 20, 2025, 4:30 AM EST - 8 months ago

Metagenomi Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Metagenomi to Present at Jefferies Global Healthcare Conference in London

Nov 17, 2025, 8:00 AM EST - 8 months ago

Metagenomi to Present at Jefferies Global Healthcare Conference in London

Metagenomi price target lowered to $7 from $11 at Chardan

2025-11-12T22:30:28.000Z - 8 months ago

Metagenomi price target lowered to $7 from $11 at Chardan

Metagenomi Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 8 months ago

Metagenomi Therapeutics Earnings release: Q3 2025

Metagenomi Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 7:00 AM EST - 8 months ago

Metagenomi Therapeutics Quarterly report: Q3 2025

Metagenomi reports new dose range finding data from MGX-001 hemophilia A program

2025-11-11T21:11:48.000Z - 8 months ago

Metagenomi reports new dose range finding data from MGX-001 hemophilia A program

Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates

Nov 11, 2025, 4:02 PM EST - 8 months ago

Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates

Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development

Nov 11, 2025, 4:01 PM EST - 8 months ago

Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development

Metagenomi taps Amazon's custom chips to develop gene-editing tools

Oct 22, 2025, 10:02 AM EDT - 9 months ago

Metagenomi taps Amazon's custom chips to develop gene-editing tools

AMZN

Metagenomi price target lowered to $11 from $12 at Chardan

2025-08-15T20:30:16.000Z - 11 months ago

Metagenomi price target lowered to $11 from $12 at Chardan

Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results

Aug 12, 2025, 4:05 PM EDT - 1 year ago

Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results

Metagenomi Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 1 year ago

Metagenomi Therapeutics Earnings release: Q2 2025

Metagenomi Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 1 year ago

Metagenomi Therapeutics Quarterly report: Q2 2025

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

Aug 11, 2025, 4:05 PM EDT - 1 year ago

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

KALV

Metagenomi Therapeutics Slides: Corporate Presentation

May 15, 2025, 8:00 AM EDT - 1 year ago

Metagenomi Therapeutics Slides: Corporate Presentation

Metagenomi price target lowered to $16 from $20 at Wells Fargo

2025-05-14T10:21:54.000Z - 1 year ago

Metagenomi price target lowered to $16 from $20 at Wells Fargo

Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025

May 14, 2025, 6:00 AM EDT - 1 year ago

Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025

Metagenomi reports Q1 EPS (68c), consensus (51c)

2025-05-13T20:41:15.000Z - 1 year ago

Metagenomi reports Q1 EPS (68c), consensus (51c)

Metagenomi sees cash, equivalents supporting operations into 2027

2025-05-13T20:41:07.000Z - 1 year ago

Metagenomi sees cash, equivalents supporting operations into 2027

Metagenomi Reports Business Updates and First Quarter 2025 Financial Results

May 13, 2025, 4:30 PM EDT - 1 year ago

Metagenomi Reports Business Updates and First Quarter 2025 Financial Results

Metagenomi Therapeutics Quarterly report: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Metagenomi Therapeutics Quarterly report: Q1 2025

Metagenomi Therapeutics Earnings release: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Metagenomi Therapeutics Earnings release: Q1 2025

Metagenomi to Present at Upcoming Scientific Meetings

May 2, 2025, 7:00 AM EDT - 1 year ago

Metagenomi to Present at Upcoming Scientific Meetings

Metagenomi Therapeutics Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Metagenomi Therapeutics Proxy statement: Proxy Filing

Metagenomi Therapeutics Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Metagenomi Therapeutics Proxy statement: Proxy Filing

Metagenomi Reports Business Updates and Full Year 2024 Financial Results

Mar 17, 2025, 4:05 PM EDT - 1 year ago

Metagenomi Reports Business Updates and Full Year 2024 Financial Results

Metagenomi Therapeutics Earnings release: Q4 2024

Mar 17, 2025, 9:30 AM EDT - 1 year ago

Metagenomi Therapeutics Earnings release: Q4 2024

Metagenomi Therapeutics Annual report: Q4 2024

Mar 17, 2025, 9:30 AM EDT - 1 year ago

Metagenomi Therapeutics Annual report: Q4 2024

Metagenomi Therapeutics Registration statement: Registration Filing

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Metagenomi Therapeutics Registration statement: Registration Filing

Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems

Mar 13, 2025, 6:19 AM EDT - 1 year ago

Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems

Metagenomi Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 5, 2025, 1:10 PM EST - 1 year ago

Metagenomi Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference

Feb 11, 2025, 8:55 AM EST - 1 year ago

Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference

Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones

Jan 16, 2025, 8:55 AM EST - 1 year ago

Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones

Metagenomi Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

Metagenomi Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Metagenomi Announces New Appointment to its Board of Directors

Jan 15, 2025, 8:55 AM EST - 1 year ago

Metagenomi Announces New Appointment to its Board of Directors

Metagenomi to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 4:05 PM EST - 1 year ago

Metagenomi to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference “RNA at the Bench and Bedside IV”

Dec 11, 2024, 6:30 PM EST - 1 year ago

Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference “RNA at the Bench and Bedside IV”

Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting

Dec 9, 2024, 9:16 PM EST - 1 year ago

Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting

MGX Deadline: MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Lawsuit

Nov 23, 2024, 1:00 PM EST - 1 year ago

MGX Deadline: MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Lawsuit

DEADLINE NEXT WEEK: Berger Montague Advises Metagenomi (NASDAQ: MGX) Investors to Contact the Firm Before November 25, 2024

Nov 22, 2024, 11:59 AM EST - 1 year ago

DEADLINE NEXT WEEK: Berger Montague Advises Metagenomi (NASDAQ: MGX) Investors to Contact the Firm Before November 25, 2024

Acs375
Acs375 Jul. 6 at 3:58 PM
$MGX i heard that a bankruptcy is incoming. how true is that?
1 · Reply
Nanu108
Nanu108 Jun. 24 at 10:57 PM
$MGX I have a large position.
0 · Reply
focafoca99
focafoca99 Jun. 5 at 7:52 PM
$MGX faces a law-firm investigation over alleged fiduciary breaches by insiders.
1 · Reply
KHG1962
KHG1962 May. 28 at 10:06 PM
$MGX four posts in one month.
0 · Reply
KHG1962
KHG1962 May. 27 at 1:29 AM
$MGX No clue why I actually own this......
0 · Reply
Sam1381
Sam1381 May. 19 at 2:10 PM
$MGX 1.24$ so far today! Historic low 1.23$ New ATLs coming I gyess!
1 · Reply
anachartanalyst
anachartanalyst May. 12 at 2:02 PM
$MGX https://anachart.com/wp-content/uploads/2026/05/1778594491_soc-img.jpg
0 · Reply
BillionerOfKing
BillionerOfKing May. 1 at 4:19 PM
$MGX Current Stock Price: $1.38
0 · Reply
MikeEhrmantraut
MikeEhrmantraut Apr. 22 at 2:27 PM
$MGX trash and pure management grift. Should be a university research department not a publicly traded company.
0 · Reply
Mindegap
Mindegap Apr. 20 at 7:50 PM
If I were short I would be nervous right now. Covering would be a very good option. $ABSI, $PRME, $MGX, $CRBU, $MXCT
1 · Reply
SuperGreenToday
SuperGreenToday Apr. 17 at 9:51 PM
$MGX
0 · Reply
Mindegap
Mindegap Apr. 17 at 2:37 PM
$MGX Great News: $MGX created a tool that for the first time combines AAV-compatible size with therapeutic-grade editing efficiency — unlocking in vivo gene editing for tissues outside the liver that have been effectively unreachable until now. This enables next-generation editors that currently can't fit in AAV at all. Published in Nature. $PRME $BEAM
0 · Reply
DARKP00L
DARKP00L Apr. 16 at 11:06 AM
$MGX 07:05 on Apr. 16 2026 Metagenomi Reports Study Showing CRISPR Editing Efficiency; Findings Support Development of Deliverable Gene Editing Systems #tradeideas
0 · Reply
MaskMaker
MaskMaker Apr. 14 at 10:53 PM
$AVXL $MGX $NXL $VTGN
0 · Reply
MaskMaker
MaskMaker Apr. 6 at 12:56 AM
$NXL $VTGN $AVXL $MGX
0 · Reply
Acs375
Acs375 Mar. 18 at 2:01 PM
$MGX Very underrated genome editing company. If MGX-001 works well in humans next year this will shoot right up.
0 · Reply
SmartMoneyTradez
SmartMoneyTradez Mar. 10 at 11:48 PM
$MGX nibbled
0 · Reply
Mindegap
Mindegap Mar. 10 at 4:23 PM
$MGX $PRME $CRBU
0 · Reply
I_am_retail_investor
I_am_retail_investor Mar. 10 at 3:25 PM
$MGX - volume is up!
0 · Reply
I_am_retail_investor
I_am_retail_investor Feb. 5 at 5:25 PM
$MGX - nice uptick in a down market, my primary thesis here being genomic informatics is recognized (at some point) as gold-like in the modern age of AI.
0 · Reply